Novartis to keep making malaria drug amid global funding crunch
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview.
The company makes 28 million malaria treatment courses every year, and sells almost all of them a not-for-profit price to countries and groups including the President's Malaria Initiative (PMI), a US-government funded initiative that still has an unclear future given President Donald President Trump's vast international aid cuts, although it did receive an exemption for some work earlier this year because of its lifesaving potential.
'We are not going to be the bottleneck,' said Dr Lutz Hegemann in an interview. 'We are not going to produce based on demand, because we know that these medicines are needed, and we need to be creative in finding ways to get them from the factory to patients.'
Earlier this year, an order was cancelled by a contractor for PMI when it got a stop-work order from the US government, Hegemann said. But then within a month it got an exception and asked for work to begin again.
'You cannot do that essentially in real-time. We remain committed to our volume,' said Hegemann, adding that this also applied for leprosy, which it donates in smaller quantities through the World Health Organization.
The Global Fund to Fight AIDS, TB and Malaria is the biggest buyer of Novartis' antimalarials. It has not yet faced cuts but is fundraising now for its future work in a difficult climate.
Speaking in London, Hegemann also urged the pharmaceutical sector to step up while governments, including the US, United Kingdom and France, pull back from aid funding, and particularly work more directly with governments that have traditionally been recipients of aid.
'I think it would be a missed opportunity if we just tried to essentially plug the gap that donor country funding has created, and I think we need to move beyond that,' he said, pointing to public-private partnerships between pharmaceutical companies and low and middle-income countries as a model.
Hegemann also said Novartis is set to spend almost double what it pledged to by the end of 2025 on malaria and neglected tropical diseases research and development: $490m rather than its pledged $250m. Products in development include a dengue antiviral, new treatments for leishmaniasis and Chagas disease, and the first malaria treatment for newborn babies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
2 days ago
- Al Arabiya
‘I am not taking drugs!' Elon Musk denies media report
Elon Musk on Saturday denied a report that he used ketamine and other drugs extensively last year on the 2024 campaign trail. The New York Times reported Friday that the billionaire adviser to President Donald Trump used so much ketamine, a powerful anesthetic, that he developed bladder problems. The newspaper said the world's richest person also took ecstasy and mushrooms and traveled with a pill box last year, adding that it was not known whether Musk also took drugs while heading the so-called Department of Government Efficiency (DOGE) after Trump took power in January. In a post Saturday on X, Musk said: 'To be clear, I am NOT taking drugs! The New York Times was lying their ass off.' He added: 'I tried 'prescription' ketamine a few years ago and said so on X, so this not even news. It helps for getting out of dark mental holes, but haven't taken it since then.' Musk first dodged a question about his drug use at a bizarre farewell appearance Friday with Trump in the Oval Office in which the Tesla and SpaceX boss sported a noticeable black eye as he formally ended his role as Trump's main cost-cutter at DOGE, which fired tens of thousands of civil servants. News of the injury drew substantial attention as it came right after the Times report on his alleged drug use. The daily recalled erratic behavior such as Musk giving an enthusiastic Nazi-style salute in January of this year at a rally celebrating Trump's inauguration. Musk said he got the injury while horsing around with his young son, named X, when he told the child to hit him in the face. 'And he did. Turns out even a five-year-old punching you in the face actually is...' he added, before tailing off. Later Friday, when a reporter asked Trump if he was aware of Musk's 'regular drug use,' Trump responded: 'I wasn't.' 'I think Elon is a fantastic guy,' he added. Musk has previously admitted to taking ketamine, saying he was prescribed it to treat a 'negative frame of mind' and suggesting his use of drugs benefited his work.
Asharq Al-Awsat
3 days ago
- Asharq Al-Awsat
Biden Optimistic After Cancer Diagnosis
Former US President Joe Biden told reporters Friday he was feeling 'optimistic' about the future after delivering his first public remarks since revealing he had an aggressive form of prostate cancer. 'Well, the prognosis is good. You know, we're working on everything. It's moving along. So, I feel good,' Biden, 82, said after an event in Delaware belatedly marking Monday's Memorial Day federal holiday. Biden's office announced earlier this month he is battling prostate cancer with a Gleason score of nine, which places him in the most severe category. The veteran Democrat told reporters he had decided on a treatment regime, adding that 'the expectation is, we're going to be able to beat this.' 'It's not in any organ, my bones are strong, it hasn't penetrated. So I'm feeling good,' he said. The mental and physical health of the former president, the oldest person ever to hold the office, was a dominant issue in the 2024 election. After a disastrous debate performance against Trump, Biden ended his campaign for a second term. When Biden's office announced his diagnosis, they said the cancer had spread to his bones. But Biden told reporters: 'We're all optimistic about the diagnosis. As a matter of fact, one of the leading surgeons in the world is working with me.' The political row over Biden's aborted candidacy has become a major scandal since the release of the book 'Original Sin' -- which alleges that Biden's White House covered up his cognitive decline while he was in office. The ex-president was asked about the controversy and responded with sarcasm, joking that 'I'm mentally incompetent and I can't walk.' He said he had no regrets about initially running for a second term, and that his Democratic critics could have challenged him but chose not to 'because I'd have beaten them.' In earlier formal remarks in New Castle, Delaware, Biden spoke of his presidency as his greatest honor, and called for better treatment of veterans. But he saved his most poignant comments to mark the 10th anniversary on May 30 of his son, National Guard veteran Beau Biden, dying of brain cancer at the age of 46. 'For the Bidens, this day is the 10th anniversary, the loss of my son Beau, who spent a year in Iraq,' said Biden, who had attended a memorial service for his son earlier in the day. 'And, to be honest, it's a hard day.'
Al Arabiya
3 days ago
- Al Arabiya
US FDA approves Moderna's next-generation COVID vaccine for adults
The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.
